Phase 3 LEAP-014: Treatment Progress for Metastatic Esophageal Cancer at ESMO 2023

Phase 3 LEAP-014 presented at ESMO 2023 demonstrates notable strides in treating metastatic esophageal cancer. The combination of lenvatinib, pembrolizumab, and chemotherapy shows promise, offering a new horizon in treatment strategies for this challenging cancer type.


By. Corina Dutcus, MD
Date. November 02, 2023

Corina Dutcus, MD, a lead investigator in the Phase 3 LEAP-014 trial for metastatic esophageal squamous cell carcinoma, presented insights into the trial's objectives, findings, and implications for patient care.

The Phase 3 LEAP-014 trial aimed to evaluate the efficacy and safety of combining lenvatinib, pembrolizumab, and chemotherapy for this cancer type, focusing on overall survival, progression-free survival, and safety measures.

Dr. Dutcus summarized the trial findings, noting improvements in overall survival, progression-free survival, and a manageable safety profile for the combination therapy.

The addition of lenvatinib and pembrolizumab to chemotherapy represents a significant advancement in the treatment landscape for this cancer type, particularly benefiting patient populations with PD-L1 expression.

Regarding safety, adverse events such as fatigue, hypertension, and manageable hematological toxicities were observed, with most being manageable with appropriate monitoring and interventions.

The data from the LEAP-014 trial implies potential shifts in standard care and future treatment strategies for metastatic esophageal squamous cell carcinoma, potentially altering treatment paradigms and improving patient outcomes.